Trial Profile

Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Caused by Heart Failure With Reduced Ejection Fraction

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carvedilol (Primary)
Indications Cardiogenic shock
Focus Therapeutic Use
Acronyms PACE-SHOCK

Most Recent Events

03 Jan 2024 Number of treatment arms are decreased from 4 to 2 by the removal of following two arms- Experimental and Active comparator arms with conservative Carvedilol administration. Primary end-point timeline is decreased from 90 days to 30 days.
03 Jan 2024 Status changed from not yet recruiting to recruiting.
18 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com